Frontiers in oncology · 2026
Primary malignant melanoma of the uterine cervix: a case report of aggressive progression despite multimodal therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Qing
Аннотация
OBJECTIVE: Primary malignant melanoma of the uterine cervix is an exceptionally rare malignancy with a biology distinct from its cutaneous counterpart and a dire prognosis. This case provides a critical in vivo model for interrogating the therapeutic resistance mechanisms inherent to mucosal melanomas.
METHODS: We report a case of a 73-year-old woman with early-stage (pT1aN0), NRAS Q61K-mutant primary cervical melanoma.
RESULTS: The patient progressed rapidly through radical surgery and adjuvant Toripalimab (anti-PD-1) immunotherapy. Despite salvage therapy with a MEK inhibitor, she succumbed to the disease 17 months after diagnosis. The sequential failure of both immune checkpoint blockade and targeted pathway inhibition highlights a dual-layer of resistance.
CONCLUSIONS: This experience mandates a fundamental re-evaluation of adjuvant strategies for this disease. It provides a compelling rationale for upfront, biology-driven combination trials (e.g., immunotherapy plus MEK or CDK4/6 inhibition) in the neoadjuvant or adjuvant setting for high-risk cases.
METHODS: We report a case of a 73-year-old woman with early-stage (pT1aN0), NRAS Q61K-mutant primary cervical melanoma.
RESULTS: The patient progressed rapidly through radical surgery and adjuvant Toripalimab (anti-PD-1) immunotherapy. Despite salvage therapy with a MEK inhibitor, she succumbed to the disease 17 months after diagnosis. The sequential failure of both immune checkpoint blockade and targeted pathway inhibition highlights a dual-layer of resistance.
CONCLUSIONS: This experience mandates a fundamental re-evaluation of adjuvant strategies for this disease. It provides a compelling rationale for upfront, biology-driven combination trials (e.g., immunotherapy plus MEK or CDK4/6 inhibition) in the neoadjuvant or adjuvant setting for high-risk cases.